Current Issue: September–October 2011
View PDF of newsletter (Download Adobe Acrobat Reader)
NEW in this issue!
A dedicated section on alcohol- and other drug-related HIV/HCV research
A dedicated section on alcohol- and other drug-related HIV/HCV research
Interventions
- Efficacy of Alcohol Brief Intervention in Primary Care by Nonphysicians
- Electronic Self-Help Interventions for Adults with Unhealthy Alcohol Use Moderately Reduce Drinking
- Alcohol and Other Drug Use Decreased During a Statewide Screening and Brief Intervention Program
- Adding Gabapentin to Naltrexone for Alcohol Dependence: No Improvement in Longer Term Outcomes
- No Clear Evidence on How Best to Manage Insomnia in People with Alcohol Dependence
Assessments
- Benzodiazepine Use among Patients Receiving Methadone Maintenance
- One in 12 US College Students Report K2 Use
Health Outcomes
- Patients with Amphetamine Use Disorders Are More Likely to Be Hospitalized or Die from Parkinson’s Disease
- Type of Alcoholic Beverage Consumed Affects Acute Pancreatitis Risk
HIV and HCV
- Naltrexone Has Little, If Any, Liver Toxicity in HIV-Infected Patients and Does Not Adversely Affect HIV Biomarkers
- Behavioral Intervention Associated with Improved Liver Enzymes in HCV-infected Young People Who Use Injection Drugs
- Combination of Substance Use Treatment and Risk Reduction Most Effective at Preventing HCV Seroconversion in People who Inject Drugs
- Counseling and Case Management Increases Eligibility for HCV Treatment
Slide Presentations
A FREE federally funded* educational service providing clinicians with a broad range of resources to address substance abuse, including
- instruments to screen patients for unhealthy substance use.
- informational materials to engage patients in conversations about substance use.
- tools that save time by pinpointing substance-abuse related problems.
- speakers for CME programs on subjects related to alcohol and drug use.
- evidence-based resources to educate future and current physicians.
*Funded by the National Institute on Drug Abuse (NIDA) and administered by the American Society of Addiction Medicine (ASAM).
